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Dear Sirs,
A 39-year-old Bangladeshi man was admitted to our hos-
pital with a first generalized epileptic seizure. Brain MRI
showed multiple ring-enhancing lesions with perifocal
edema (Fig. 1a and g, February 2008). CSF analysis
showed 8 cells/ll and normal protein, glucose and lactate
levels. Serum and CSF serological tests were negative for a
broad range of parasites, fungi and bacteria.
The patient was suspected to have neurocysticercosis
and was treated with albendazole (400 mg bi-daily for
30 days). However, follow up MRI showed new, adjacent
lesions with ring- and tunnel-shaped enhancement; and
punctate calcifications in the left parieto-occipital area in
the CT scan (Fig. 1b, h and m, December 2009), suggesting
that the treatment had been ineffective. We therefore per-
formed a brain biopsy (with prior MRI for the localization
of the sparganum, see Fig. 1c and i, February 2010), which
revealed a degenerated cyst containing membrane-shaped
structures with multiple foci of calcification. PCR was
positive for Spirometra erinaceieuropaei, leading to the
diagnosis of cerebral sparganosis.
Surgical removal of the parasite is the treatment of
choice as standard anti-helmintic therapy is considered
ineffective in sparganosis [1–3]. The repeated MRI indi-
cated that the lesion had been wandering again (Fig. 1d and
j). An ethylcholine PET showed a defined region with
increased tracer uptake, most likely indicating the current
location of the sparganum (Fig. 1n). However, the patient
refused the recommended stereotactic surgery. We there-
fore treated the patient with a high-dose regimen of pra-
ziquantel (3 9 25 mg/kg body weight daily) for 7 days
combined with cimetidine (3 9 400 mg daily) and a high
carbohydrate diet to increase plasma levels of praziquantel
[4]. The treatment was well-tolerated.
Follow-up MRIs 3 and 11 months later showed drastic
improvement and the ethylcholine PET had normalized
(Fig. 1e, f, k, l, o and p). Anti-sparganum antibody levels
were determined from preserved CSF and serum samples
by a specific ELISA [5]. Before therapy (Fig. 1, December
2009), anti-sparganum antibody levels were elevated in the
serum (0.29) and in the CSF (0.55 normal value in serum
and CSF \ 0.22). After therapy (Fig. 1, June 2011), anti-
body levels had dropped to 0.09 in serum (a lumbar
puncture was not repeated after therapy). Seizures dis-
continued and anticonvulsive treatment was slowly
tapered.
Sparganosis is a rare parasitic disease caused by infes-
tation with the larval cestode of Spirometra spp. Most cases
have been reported in Southeast and Eastern Asia. Humans
are infected by drinking unfiltered, contaminated water or
through consumption of raw snakes and frogs. When the
parasite invades the central nervous system, epileptic sei-
zures and headache are common symptoms [2]. Charac-
teristic MRI findings of cerebral sparganosis include a
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‘tunnel sign’, and ‘wandering lesions’ on successive ima-
ges representing the track of motion of the parasite [6, 7].
The treatment of choice for cerebral sparganosis is
surgical removal because treatment with anti-helminthics,
including praziquantel, has been described as not effective
[1–3]. In our patient the clinical improvement, and the
normalization of brain imaging and of anti-sparganum
antibody levels suggest that the parasite was eradicated by
high-dose praziquantel therapy. Although the close tem-
poral correlation of therapy and presumed death of the
parasite suggests a causal relationship we cannot rule out
the possibility that this was, in fact, due to a coinciding,
natural death of the parasite and not due to the chemo-
therapeutics. There is no information regarding the ces-
tode’s life expectancy in human tissue in the literature.
Cerebral sparganosis should be suspected in patients
from endemic areas with indications of cerebral parasitic
infection and ‘‘wandering lesions’’ in the MRI. High-dose
praziquantel treatment may be considered in inoperable
cases of cerebral sparganosis. Ethylcholine PET can be
used preoperatively for the precise localization of the
sparganum. This should be particularly valuable if the
precise location is not known due to the often multifocal
lesions in MRI.
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Fig. 1 Radiology findings. The upper and middle row show axial
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Repeated ethylcholine PET scans before and 3 and 11 months after
praziquantel therapy are shown in (n–p). The relative amount of
tracer uptake is color-coded with arbitrary units
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